Regulus Announces Strategic Update and Corporate Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Regulus Therapeutics (RGLS) PT Lowered to $0.50 at Wells Fargo
July 6, 2018 8:27 AM EDTWells Fargo analyst Jim Birchenough lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $0.50 (from $1.50) while maintaining a Market Perform rating following todays interruption of the phase 1 study of anti-miR therapeutic RGLS4326 in autosomal dominant polycystic kidney disease (ADPKD) following unexpected preclinical... More
Regulus Therapeutics (RGLS) Falls 38% as Trading Resumes
July 5, 2018 5:33 PM EDTRegulus Therapeutics (NASDAQ: RGLS) sinks 38% as trading resumes following restructuring and massive job cuts.
... MoreRegulus Therapeutics (RGLS) to Resume Trading at 5:30 pm ET
July 5, 2018 5:03 PM EDTRegulus Therapeutics (NASDAQ: RGLS) to Resume Trading at 5:30 pm ET
... More